V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330011383 | 330003917 | 1.74 | 14.55 | Palliative (P) | 2015-02-27 | 2015-12-25 | DOXORUBICIN | 2 | N | 330007794 | DOXORUBICIN |
| 330011384 | 330008123 | 1.61 | 56 | null | 2017-05-13 | 2017-06-11 | Cisplatin | N | N | 330007804 | CISPLATIN |
| 330011385 | 330011674 | 1.72 | 89.2 | Curative (C) | 2017-02-17 | 2017-02-17 | Trial Unspecified | 02 | N | 330007831 | TRIAL |
| 330011386 | 330003924 | 1.76 | 84 | Neo-adjuvant (N) | 2017-07-21 | 2017-09-30 | Cisplatin | 2 | N | 330007879 | CISPLATIN |
| 330011387 | 330008130 | 1.66 | null | Neo-adjuvant (N) | 2015-05-27 | 2015-06-07 | Cisplatin | N | N | 330007891 | CISPLATIN |
| 330011388 | 330003929 | 1.88 | 62.5 | Curative (C) | 2016-07-09 | 2016-08-19 | METHOTREXATE | 02 | N | 330007899 | METHOTREXATE |
| 330011389 | 330008135 | 1.81 | null | Adjuvant (A) | null | 2017-12-27 | METHOTREXATE | null | null | 330007924 | METHOTREXATE |
| 330011390 | 330003938 | null | 86 | Palliative (P) | null | 2017-08-28 | METHOTREXATE | 2 | Y | 330007962 | METHOTREXATE |
| 330011391 | 330003940 | 1.7 | 61 | Curative (C) | 2014-07-28 | 2014-07-29 | OST Euramos 1 Closed Trial - IE | N | N | 330007971 | TRIAL |
| 330011393 | 330003949 | 1.68 | null | Palliative (P) | 2014-12-25 | 2014-12-25 | Trial Unspecified | 02 | Y | 330007988 | TRIAL |
| 330011394 | 330011679 | 1.59 | null | Palliative (P) | 2012-01-18 | 2013-06-08 | EW EuroEwing 2012 Arm B IE | null | null | 330008011 | TRIAL |
| 330011395 | 330003953 | 1.7 | 81 | Disease modification (D) | 2016-09-05 | 2016-09-30 | Trial Unspecified | N | N | 330008012 | TRIAL |
| 330011396 | 330003955 | 1.82 | 95.35 | Adjuvant (A) | 2015-05-06 | 2016-12-17 | Mifamurtide weeks 13-36 | N | N | 330008037 | MIFAMURTIDE |
| 330011397 | 330008153 | 0 | 89.8 | Neo-adjuvant (N) | 2018-11-13 | 2018-11-13 | MIFAMURTIDE | N | N | 330008049 | MIFAMURTIDE |
| 330011398 | 330003962 | 1.7 | 91 | Curative (C) | 2014-10-13 | 2014-12-30 | Cisplatin | N | N | 330008050 | CISPLATIN |
| 330011399 | 330003963 | null | 64.1 | Curative (C) | 2017-04-29 | 2017-04-30 | EW EuroEwing 2012 Arm A VAI | N | null | 330008053 | TRIAL |
| 330011400 | 330010428 | 1.63 | 61.45 | Adjuvant (A) | null | 2017-06-05 | OST Mifamurtide | N | null | 330008066 | MIFAMURTIDE |
| 330011401 | 330010430 | 1.63 | null | Adjuvant (A) | null | 2015-01-30 | METHOTREXATE | Y | N | 330008090 | METHOTREXATE |
| 330011402 | 330003969 | 1.6 | 18.1 | Curative (C) | 2014-01-14 | 2015-02-10 | Mifamurtide weeks 13-36 | 02 | N | 330008095 | MIFAMURTIDE |
| 330011403 | 330003971 | 1.77 | 63 | Curative (C) | 2013-05-02 | 2013-05-07 | Cisplatin 7 day | N | N | 330008104 | CISPLATIN |
| 330011404 | 330003973 | 1.54 | 37.8 | Palliative (P) | null | 2017-03-24 | METHOTREXATE | Y | N | 330008116 | METHOTREXATE |
| 330011406 | 330003978 | 1.75 | 75.4 | Adjuvant (A) | 2013-09-28 | 2014-02-15 | Cisplatin 7 day | Y | null | 330008124 | CISPLATIN |
| 330011407 | 330003981 | 1.88 | 50.3 | Curative (C) | 2018-03-08 | 2018-04-05 | Cisplatin | N | null | 330008126 | CISPLATIN |
| 330011408 | 330003983 | 1.78 | 95.35 | Curative (C) | null | 2016-09-01 | METHOTREXATE | N | null | 330008133 | METHOTREXATE |
| 330011409 | 330003984 | 1.78 | 22 | Palliative (P) | 2018-04-01 | 2018-04-02 | Methotrexate + Folinic acid | 2 | N | 330008137 | METHOTREXATE |
| 330011410 | 330003985 | 0 | null | Palliative (P) | 2014-03-09 | 2014-03-09 | OST Mifamurtide | 02 | N | 330008138 | MIFAMURTIDE |
| 330011411 | 330003988 | 1.65 | 56 | Neo-adjuvant (N) | 2014-03-14 | 2014-05-16 | METHOTREXATE | 2 | Y | 330008146 | METHOTREXATE |
| 330011412 | 330003991 | null | 101 | Curative (C) | 2012-12-23 | 2014-01-30 | DOXORUBICIN | N | N | 330008152 | DOXORUBICIN |
| 330011413 | 330003997 | 1.72 | 42.4 | Curative (C) | 2016-03-20 | 2016-03-28 | Mifamurtide weeks 1-12 | 2 | Y | 330008194 | MIFAMURTIDE |
| 330011414 | 330004005 | 1.79 | null | Adjuvant (A) | 2016-01-08 | 2016-09-12 | OST Mifamurtide | 01 | N | 330008198 | MIFAMURTIDE |
| 330011415 | 330004009 | 1.64 | 62.65 | Palliative (P) | 2012-07-16 | 2014-08-19 | METHOTREXATE | Y | Y | 330008208 | METHOTREXATE |
| 330011416 | 330004011 | 1.92 | null | Curative (C) | 2014-03-02 | 2014-03-02 | OST Euramos 1 Closed Trial - IE | 2 | Y | 330008219 | TRIAL |
| 330011417 | 330004015 | 1.82 | 56 | Palliative (P) | null | 2017-09-16 | DOXORUBICIN | null | null | 330008235 | DOXORUBICIN |
| 330011418 | 330004020 | null | 58.6 | Adjuvant (A) | 2017-05-05 | 2017-05-05 | MIFAMURTIDE | 01 | N | 330008263 | MIFAMURTIDE |
| 330011419 | 330004025 | 0 | 77.8 | Curative (C) | 2016-02-08 | 2016-03-05 | Cisplatin 7 day | N | null | 330008268 | CISPLATIN |
| 330011420 | 330004027 | null | 60.7 | Palliative (P) | 2017-02-26 | 2017-04-15 | CNS Medbl HR Cyclo+Vinc | null | null | 330008284 | TRIAL |
| 330011421 | 330004031 | null | 91.8 | Neo-adjuvant (N) | 2014-09-28 | 2014-10-18 | METHOTREXATE | null | N | 330008298 | METHOTREXATE |
| 330011422 | 330010448 | null | 61.4 | Curative (C) | 2016-10-21 | 2016-10-22 | Trial Unspecified | N | Y | 330008309 | TRIAL |
| 330011423 | 330004036 | 0 | 74 | Neo-adjuvant (N) | 2016-09-21 | 2017-02-27 | OST Euramos 1 Closed Trial - AP | N | N | 330008321 | MAP |
| 330011425 | 330004042 | 1.63 | 48.6 | Neo-adjuvant (N) | 2017-03-01 | 2017-08-10 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330008370 | MAP |
| 330011426 | 330004046 | null | 54 | Curative (C) | 2015-12-10 | 2016-05-08 | PAM x 2 post-surgery (cycles 3&4) | Y | null | 330008372 | MAP |
| 330011427 | 330008205 | 1.8 | 66 | Palliative (P) | 2017-01-07 | 2017-01-07 | CISPLATIN + FLUOROURACIL | N | N | 330008382 | CISPLATIN + FLUOROURACIL |
| 330011428 | 330004054 | 1.45 | 87.35 | Curative (C) | 2018-01-24 | 2018-02-21 | OST Euramos 1 Closed Trial - M | null | N | 330008390 | METHOTREXATE HIGH DOSE |
| 330011429 | 330004056 | 1.66 | 42.7 | Curative (C) | 2015-08-01 | 2015-08-05 | Methotrexate High Dose (3g/m2) | N | N | 330008395 | METHOTREXATE HIGH DOSE |
| 330011430 | 330008215 | 1.54 | 68.2 | Neo-adjuvant (N) | 2017-11-29 | 2018-03-17 | Cetuximab 7 day (Cycle 1) | N | N | 330008495 | CETUXIMAB |
| 330011432 | 330004071 | 1.67 | 86.8 | Adjuvant (A) | 2017-09-01 | 2018-05-23 | Etoposide + Ifosfamide (3 days) | N | N | 330008566 | ETOPOSIDE + IFOSFAMIDE |
| 330011433 | 330008220 | 1.74 | null | Curative (C) | 2015-12-08 | 2016-07-28 | ETOPOSIDE + IFOSFAMIDE | Y | N | 330008567 | ETOPOSIDE + IFOSFAMIDE |
| 330011434 | 330004081 | null | 87.8 | Curative (C) | null | 2018-06-02 | Carboplatin AUC 6 - 10 | N | N | 330008603 | CARBOPLATIN |
| 330011435 | 330004082 | 1.67 | 0 | Curative (C) | 2015-08-21 | 2015-09-17 | OST Euramos 1 Closed Trial - AP | 02 | N | 330008614 | MAP |
| 330011436 | 330008227 | 1.71 | 90 | Palliative (P) | 2016-01-02 | 2016-02-24 | CARBOPLATIN | N | N | 330008687 | CARBOPLATIN |